

Application of Fragment-Based Drug Discovery to Membrane Proteins: Identification of Ligands of the Integral Membrane Enzyme DsbB

Virginie Früh,¹ Yunpeng Zhou,² Dan Chen,³ Caroline Loch,³ Eiso AB,³ Yelena N. Grinkova,⁴ Herman Verheij,⁵ Stephen G. Sligar,⁴ John H. Bushweller,^{2,6} and Gregg Siegal^{1,*}

¹Leiden Institute of Chemistry, Leiden University, Leiden 2300RA, The Netherlands

²Department of Molecular Physiology and Biological Physics, University of Virginia, Charlottesville, VA 22908, USA

³ZoBio BV, Leiden 2300RA, The Netherlands

⁴University of Illinois, 116 Morrill Hall, 505 S. Goodwin Avenue, Urbana, IL 61801, USA

⁵Pyxis Discovery, 2628XH Delft, The Netherlands

⁶Department of Chemistry, University of Virginia, Charlottesville, VA 22908, USA

*Correspondence: g.siegal@chem.leidenuniv.nl

DOI 10.1016/j.chembiol.2010.06.011

SUMMARY

Membrane proteins are important pharmaceutical targets, but they pose significant challenges for fragment-based drug discovery approaches. Here, we present the first successful use of biophysical methods to screen for fragment ligands to an integral membrane protein. The *Escherichia coli* inner membrane protein DsbB was solubilized in detergent micelles and lipid bilayer nanodiscs. The solubilized protein was immobilized with retention of functionality and used to screen 1071 drug fragments for binding using target immobilized NMR Screening. Biochemical and biophysical validation of the eight most potent hits revealed an IC_{50} range of 7–200 μ M. The ability to insert a broad array of membrane proteins into nanodiscs, combined with the efficiency of TINS, demonstrates the feasibility of finding fragments targeting membrane proteins.

INTRODUCTION

With 60% of currently marketed drugs targeting membrane proteins (Zheng et al., 2006), it is clear that finding small molecules to modulate the function of such proteins is essential. High throughput screening (HTS) methods have been successful in identifying such compounds, but because the methods of detection rely on functional assays, they are generally only sensitive to submicromolar interactions. Such relatively tight interactions are generally only observed for larger compounds (300–500 Da). However, it has proved challenging to simultaneously optimize potency and absorption, distribution, metabolism, and excretion (ADME) properties of these “lead-like” or “drug-like” compounds. Furthermore, such large compounds inefficiently explore the binding sites of proteins (Carr et al., 2005). Fragment-based drug discovery (FBDD) has become a powerful complementary approach to HTS for generating novel

chemical modulators of pharmaceutical targets. FBDD screens small libraries (1000–20,000 compounds) of so-called drug “fragments” that are often described by a “rule of threes” (Congreve et al., 2003) (Ro3, M_r <300 Da, cLogP <3, H-bond donors <3, H-bond acceptors <3, number of rotatable bonds <3 and TPSA (total polar surface area) <60 \AA^2) for binding to the target. Ro3-compliant compounds typically bind the target with K_D greater than 10 μ M. In order to detect such weak binding, sensitive biophysical techniques are typically required, particularly when the target is not an enzyme. Commonly used techniques for detecting fragment binding include NMR, X-ray crystallography, and surface plasmon resonance (SPR) (Siegal et al., 2007).

Although biophysical methods have been successfully applied to an array of soluble protein targets (Hajduk et al., 1997), they have failed in one way or another when applied to membrane proteins. There are two primary reasons for this failure: insufficient quantity of the target and problems related to the solubilization media. Many biophysical methods require tens or even hundreds of milligrams of purified, functional protein and most membrane proteins are difficult to produce in these quantities. However, recent advances have enabled the production of low milligram quantities of a variety of MPs (Rasmussen et al., 2007; Serrano-Vega et al., 2008; Dahmane et al., 2009). Membrane proteins that can be produced in sufficient quantity must then be solubilized in a surfactant while maintaining their functional state, which is also often challenging. Finally, nonspecific partitioning of fragments into the surfactant has been a severe problem leading to high levels of false positives.

The use of detergent micelles to solubilize MPs has only met limited success in retaining the native function of the protein while at the same time the micelles often interfere with biophysical assays. A possible solution to this bottleneck would be to employ nondetergent media to functionally solubilize MPs. The nanodisc (ND) has been developed as an alternative, surfactant-free approach to solubilize MPs. NDs consist of a lipid bilayer that is surrounded by an amphiphilic α -helical membrane scaffold protein (MSP). A variety of proteins have been functionally solubilized in NDs (Nath et al., 2007; Katzen et al., 2008; Leitz et al., 2006), which are much better mimics of the native

membrane than detergent micelles. However, the suitability of NDs for biophysical assays of ligand binding to MPs has yet to be determined.

We have developed an NMR-based fragment screening approach which has proven capable of overcoming many of the challenges posed by membrane proteins (Früh et al., 2008). The approach, called target immobilized NMR screening (TINS) (Vanwetswinkel et al., 2005), involves immobilizing a target and a reference in two compartments of a dual-cell sample holder (Marquardsen et al., 2006) and simultaneously injecting mixtures of fragments in an automated process. For each mixture, a 1D ^1H NMR spectrum is recorded while fragment binding to the target protein results in a decrease in peak amplitude. The reference, which is selected for minimal specific small molecule binding, serves to cancel out nonspecific binding of fragments to protein surfaces. Hits can therefore be detected by comparing spectra of the compounds recorded in the presence of the target to those recorded in the presence of the reference. By repeatedly using the same sample to screen the entire fragment collection (>1000 compounds), typically only ~25 nmol of protein is required, thus bringing many MPs within the requirements for TINS. Furthermore, the reference system is expected to account for nonspecific binding of fragments to the media in which the membrane protein is solubilized.

We sought to apply TINS to a bona fide, integral membrane pharmaceutical target that could be functionally solubilized in detergent micelles and NDs. The inner membrane protein of *E. coli* disulphide bond forming protein B (DsbB), and its homologs in other Gram-negative bacteria, is an oxidoreductase that is essential for protein disulfide bond formation in the periplasm (Bardwell et al., 1993). Periplasmic DsbA functions as the catalyst for protein disulfide bond formation and is reoxidized by DsbB with concomitant reduction of bound ubiquinone or menaquinone. Since many bacterial virulence factors are secreted proteins that require disulfide bonds for proper folding and function, the DsbA/DsbB system is a potential antimicrobial drug target (Inaba and Ito, 2002; Stenson and Weiss, 2002; Jaguszyn-Krynicka et al., 2009). DsbB is an ideal candidate to test the TINS methodology since it can be produced in large quantities and solubilized in detergent micelles where it retains a robust enzymatic activity which is easily assayed. In addition, a wealth of biochemical data is available that describes the enzymatic activity of the wild-type as well as numerous relevant mutants (Jander et al., 1994; Bardwell et al., 1993; Regeimbal and Bardwell, 2002; Kadokura et al., 2000). Finally, the 3D structures of wild-type DsbB bound to its redox partner DsbA (Inaba et al., 2006) and of a mutant representing an enzymatic intermediate are available (Zhou et al., 2008). Selection of an appropriate reference system is critical to insure the robust performance of TINS. Our previous experience using the *E. coli* outer membrane protein A (OmpA) transmembrane domain, which has native structure under the same detergent micelle conditions as DsbB (Arora et al., 2001), suggested that it had minimal small molecule binding and would therefore serve as a good reference (data not shown).

Here, we report the first complete screen of a fragment library against an integral membrane protein. We have tested the applicability of TINS for fragment screening using both micelle and ND-solubilized protein. Hits from the screen have been validated

and characterized with respect to mode of action using an enzyme inhibition assay. Finally, the binding mode of two classes of inhibitors has been investigated by analysis of chemical shift perturbations induced upon fragment binding to ^{15}N -labeled mutant DsbB.

RESULTS

DsbB Functional Immobilization and Enzymatic Activity

Wild-type DsbB (containing endogenous quinone) has previously been solubilized in DPC micelles, which we refer to as DsbB/DPC, with retention of enzymatic function (Zhou et al., 2008). We prepared protein similarly and immobilized it on a Sepharose resin via a Schiff's base intermediate. At the pH selected (7.4), this reaction is relatively specific for the free N terminus. A final concentration of approximately 100 μM DsbB/DPC (nmol protein per milliliter settled bed volume) was achieved with an overall yield of 50%. The functionality of the immobilized enzyme was compared to nonimmobilized, micelle-solubilized enzyme. The immobilized wild-type DsbB/DPC retained 90% activity in comparison to the nonimmobilized protein and the k_{cat} of both forms of the protein was close to values previously reported (Bader et al., 2000). The ready immobilization with retention of enzymatic activity suggests that the N terminus of DsbB is accessible in the micelle-solubilized protein. We used the same approach to immobilize OmpA which had also been solubilized in DPC micelles (Arora et al., 2002) and shown to be natively folded. We observed a similar yield of OmpA immobilization. Since OmpA has no enzymatic activity, we had to assume that its structure was not grossly perturbed by the immobilization process. Independent experiments showed that immobilized samples of DPC-solubilized DsbB were stable for at least one month after storage at 4°C (data not shown).

We next trapped DPC-solubilized DsbB and OmpA in NDs. Gel filtration analysis of our preparations revealed Stokes diameters of 9.63, 9.68, and 9.52 nm for empty NDs (–/ND), NDs with embedded DsbB (DsbB/ND), and NDs with embedded OmpA (OmpA/ND), in accordance with literature values (Civjan et al., 2003) (see Supplemental Information available online). We determined a stoichiometry of 1 DsbB per ND by densitometric scanning of gels of the preparations. The DsbB/ND was immobilized using the same method as for DsbB/DPC with an overall yield of 75%. Nonimmobilized and immobilized DsbB/ND were assayed for enzymatic activity for comparison to DsbB/DPC. Both DsbB/ND preparations had a k_{cat} that was somewhat greater than the micelle-solubilized protein, indicating that they remained completely functional (Supplemental Information). The increased k_{cat} for DsbB in NDs could possibly result from a more native functionality of the enzyme in the lipid bilayer environment of the ND.

Stability of the Immobilized Protein to Repeated Sample Application Cycles

In a method such as TINS where a single sample of the target is used to screen an entire compound collection, the integrity of the immobilized protein is clearly critical. Soluble proteins are routinely stable over more than 200 cycles of sample application and washing (Vanwetswinkel et al., 2005). Solubilized MPs




Figure 1. Stability of the DsbB in Micelles and NDs

The stability of DPC-solubilized (A) and ND-solubilized (B) DsbB after multiple cycles of compound application and washing was assessed by binding of a known ligand, UQ1. Binding is displayed as the average ratio of peak heights for the compound in the presence of DsbB over that in the presence of the reference (T/R ratio). The reference in (A) was DPC-solubilized OmpA and in (B) –/ND. Note the difference in vertical scale between (A) and (B). See also Tables S1 and S2, and Figure S1.

however, include two components, the surfactant and the protein itself, both of which must remain stable in order to ensure proper ligand screening. Preliminary studies of DsbB/DPC and OmpA/DPC clearly demonstrated that repeated cycles of compound application and washing in the absence of added detergent resulted in rapid degradation of DsbB activity (Früh et al., 2008). Therefore, deuterated DPC was included at a minimum concentration of 5 mM (approximately three times the critical micellar concentration) in the buffer used to wash the compounds from the sample holder. The library, which consisted of 1071 fragments at the time, was then screened in mixtures that averaged approximately five compounds each in the absence of DPC. Including control experiments designed to monitor the physical integrity of the target and reference samples, approximately 200 sample application/washing cycles were performed. To monitor the integrity of the DsbB sample during the screen, the binding of synthetic UQ1 was observed (Figure 1A). In TINS, binding of a fragment is best described by the T/R (target/reference) ratio, defined as the average ratio of the amplitude of peaks in the presence of the target, DsbB, to that in the presence of the reference, OmpA. It is clear from Figure 1A that binding of UQ1 to DsbB/DPC remained relatively constant throughout the screen which required 5.5 days to complete.

Since it was not practical to rescreen the entire fragment collection multiple times, we selected a subset of 20 compound mixtures containing positive hits from the DsbB/DPC screen and 20 mixtures containing no positive hits from the DsbB/DPC screen (a total of 183 compounds) to assess the suitability of the ND system for ligand screening. The 40 mixes, along with the control experiments used for DsbB/DPC, were applied sequentially to the immobilized DsbB/ND using –/ND as the reference. We wanted to assess whether DsbB/ND and –/ND were stable in the absence of added phospholipid. As with DsbB/DPC, we monitored the integrity of DsbB/ND, as determined by binding of a known ligand (UQ1), during multiple cycles of compound application and washing in lipid-free buffers. The T/R ratio for ligand binding to DsbB/ND versus –/ND is shown in Figure 1B. These data suggest a possible, initial small degradation in binding behavior (although the variation is similar to that seen in Figure 1A), after which the ligand binding capacity of DsbB/ND remained constant. Alternatively, the small possible decrease in ligand binding could be explained by the combination of a high-affinity binding mode, in which the ligand is ineffi-

ciently removed by washing, and a low-affinity binding mode. The constant T/R ratio during cycles 22 through 61 suggests that both DsbB/ND and –/ND remained intact.

Target Immobilized NMR Screening of DsbB/DPC

The fragment collection was screened for binding to DsbB at 500 μ M each, in 182 mixtures. A spatially selective Hadamard NMR experiment (Murali et al., 2006) was used to simultaneously acquire a 1D 1 H spectrum of compounds in the presence of DsbB/DPC or OmpA/DPC. The data resulting from the screen could be analyzed directly without deconvolution because fragments could be directly identified by comparing peaks from TINS spectra with reference spectra of the individual fragment (Figure 2). The screen resulted in 93 hits for DsbB, defined as fragments which had a T/R ratio less than 0.3, as shown by an example of a mix containing two hits in Figure 2. This particular cutoff was chosen by virtue of a step-like relationship between the observed TINS effect and the number of “hits” whereby even slightly raising the cutoff gave a large increase (>2-fold) in the number of compounds that were selected as hits (not shown). The resulting hit rate for DsbB was 8.7% which is well within the range we typically observe with soluble proteins using TINS (3%–9.5%). Application of the same criteria to OmpA/DPC binding identified seven compounds as hits for a hit rate of 0.6%, validating the earlier data suggesting that OmpA/DPC has minimal small molecule binding capacity.

Comparison of Micelle-Solubilized versus ND-Solubilized Protein for Ligand Binding Studies

The influence of detergent or ND on the quality of the NMR spectra of the fragments is shown in Figures 2D and 2E. In both cases, the compound whose spectrum is shown in Figure 2C can be identified as specifically binding to DsbB. However, the signal-to-noise ratio of the compounds (Figures 2A and 2B) in Figure 2E is nearly double that in Figure 2D (most readily observed on the aromatic resonances, but see also the peak at 3.1 ppm). The improved quality of the spectra allows more reliable analysis of the peaks at 7.3 and 7.4 ppm, which are now clearly seen to indicate specific binding of this compound to DsbB/ND, consistent with the behavior of the peaks at 2.8 and 2.2 ppm. The reduced signal in the presence of detergent-solubilized protein is likely due to nonspecific partitioning of 30%–40% of the compounds into the micelle.




Figure 2. Detection of Ligand Binding to Immobilized DsbB Using TINS

The 1D ¹H NMR spectrum of three different fragments in solution (A–C) is shown for reference. The ¹H NMR spectrum of a mix of the three fragments in the presence of DsbB/DPC (red spectrum) or OmpA/DPC (blue spectrum) that have been immobilized on the Sepharose support is shown in (D). The spectra of the same mix recorded in the presence of DsbB/ND (green) or –/ND (magenta) is shown in (E). The asterisk indicates the resonance from residual ¹H DMSO and the bracket shows residual sugar ¹H resonances from the Sepharose media. The residual H₂O resonance at 4.7 ppm has been filtered out.

The stability of the empty ND (–/ND) as shown in Figure 1B affords the possibility to use NDs directly as a generic reference to account for nonspecific ligand binding to the phospholipid bilayer and the scaffolding protein. To investigate this, we screened all 183 compounds for binding to DsbB/ND using either OmpA/ND or –/ND as a reference. By plotting the T/R for each compound from the screen using –/ND versus that of using OmpA/ND, we derive a 2D plot that gives an overview of the performance of the screen (Figure 3A). Overall there was a reasonable correlation in ligand binding to DsbB/ND using either empty NDs or OmpA/ND as the reference ($R^2 = 0.78$). In general, however, the T/R ratio of fragments is lower with –/ND as a reference, indicating that specific binding to DsbB/ND is more pronounced. Since the NMR spectra of the fragments in the presence of DsbB/ND in the screen versus –/ND or OmpA/ND are similar, this suggests a higher level of nonspecific binding of the fragments to OmpA/ND. We conclude therefore that –/ND is the preferred reference.

We then compared the ligand screening results from DsbB/DPC (OmpA/DPC as reference) to those from DsbB/ND (–/ND as reference). Upon inspection of the raw NMR data from the DPC screen, we observed that although 183 compounds were

present in the 40 mixes selected, only 127, about two-thirds, gave observable NMR spectra. Presumably, those compounds missing from the NMR data had nonspecifically adsorbed to the micelle. We compared the calculated Log of the octanol/water partition coefficient (cLogP) for compounds that could be observed (median 0.9) and could not be observed (median 1.8) for evidence to support this assumption. Despite the inaccuracies of cLogP values, there is a clear trend toward more hydrophobic compounds in the group of compounds whose NMR spectra were unobservable in the presence of micelles. In contrast, 164 of 183 compounds gave observable spectra in the ND screen. The median cLogP for the observable compounds was 1.1 and 1.6 for the unobservable. However, the small size of the set of unobservable compounds in the presence of ND renders the median cLogP value meaningless. Of the 127 compounds with observable spectra in the DPC screen, 70 were of sufficiently high quality to allow a reliable comparison with the ND screen, and we therefore focused our efforts on these. Inspection of Figure 3B clearly shows that the correlation between the micelles and NDs is much less pronounced than between the two ND references. Using the same criteria for hit selection for both, 22 hits were identified for DsbB/ND and 22 were identified for DsbB/DPC. Of these biophysically detected hits, 14 were common to both the micelle and ND (red) screen while 8 were unique to the ND screen (blue) and 8 were unique to the micelle screen (green, see also Table 1). We analyzed




Figure 3. Comparison of TINS Screening in Micelles versus NDs

A total of 70 fragments were assayed for binding to DsbB solubilized in either detergent micelle or ND. (A) The 70 fragments were screened for binding to DsbB/ND using either empty ND (–/ND) or OmpA/ND as a reference. The T/R (see text) for each compound is plotted for one screen versus the other. $R^2 = 0.78$.

(B) The T/R for each compound in the DsbB/ND versus –/ND screen is plotted against the value from the DsbB/DPC versus OmpA/DPC screen. Hits common to both screens are shown in red. Hits found only in the ND screen are shown in blue while those found only in the DPC screen are in green.

Table 1. Fragment Hits from the Screen of DsbB in Micelles and NDs

| | Hits | cLogP | BioAssay in ND | BioAssay in DPC |
|---------|------|-------|----------------|-----------------|
| Micelle | 8 | 1.34 | – | + |
| ND | 8 | 2.21 | ++ | ++ |
| Both | 14 | 2.13 | ++ | ++ |

Note: –, poor correlation between enzyme inhibition and binding assay; +, reasonable correlation (approximately 50% hits bioactive); ++, good correlation (80%–90% bioactive); cLogP is the median value.

the solubility of each of the 22 fragment hits using the cLogP. Interestingly, the hits specific for the ND screen are on average slightly more hydrophobic than the hits found in both screens, but the hits specific to the micelle screen are considerably more hydrophilic (Table 1). A possible explanation for this observation is that the more hydrophobic fragments exhibited greater nonspecific binding to the micelle, thus masking specific binding to DsbB. This observation is consistent with the NMR data in Figure 2. Using the same criteria, 2 out of the 183 compounds assayed bound to –/ND (1.1% hit rate). Given the small sample, this hit rate is similar to that for OmpA/DPC.

Hit Validation Using Enzymatic Assays

The TINS assay simply identifies compounds that bind to DsbB, but not necessarily in a biologically relevant manner. Therefore, we felt it was critical to validate the hits in terms of biological activity. We used an enzymatic assay to assess the ability of the compounds to inhibit electron transfer mediated by DsbB. Each of the 93 fragments identified as TINS hits in the micelle screen was assayed for inhibition of DsbB-dependent reoxidation of DsbA at 250 μ M (Supplemental Information). Eight compounds interfered with the assay when run in either fluorescence or absorbance mode and therefore were left out of the analysis. The remaining 85 hits exhibited a distribution of potencies against DsbB, including 60% with better than 30% enzymatic inhibition and 16% with either less than 20% inhibition or stimulation. These data confirm that a very high percentage of the hits found in the biophysical assay also modulate the enzymatic activity of DsbB and are functionally relevant.

We next used the inhibition assay to compare hits selected in the micelle screen to those selected in the ND screen (see Table 1). As expected, fragments common to both the micelle and ND screens yielded a strong correlation with biological activity with 12/14 exhibiting medium (30%–70%) or high (>70%) inhibition of DsbB in both micelles and NDs. We observed a good correlation between ligands detected in the ND screen and biochemical activity against both micelle and ND-solubilized DsbB where six of seven compounds had medium inhibitory activity and the seventh was a mild stimulator. In contrast, while the micelle-specific ligands correlated reasonably well with the bioassay using detergent-solubilized DsbB where five of eight were medium or strong inhibitors, none inhibited DsbB/ND.


To avoid the possibility of artifacts in the biochemical assay, we selected the 13 fragments from the micelle screen showing strong inhibition in the single concentration point assay for further analysis. We first assayed these 13 fragments for potency (IC_{50}) by dose-response experiments (Figure 4; Supplemental

Information). Dose-response experiments were carried out with increasing fragment concentrations, from 0.0001 to 10 mM, while both DsbA and UQ1 were kept in excess. Three of the 13 fragments indeed showed artifacts including signs of protein precipitation at higher compound concentration and/or steeper than expected Hill coefficients. The remaining ten fragments titrated over 2 Log orders and exhibited a Hill coefficient close to unity. By these criteria, the ten fragments are reversible inhibitors with a 1:1 stoichiometry and are therefore well behaved. The eight most potent compounds had IC_{50} values between 7 and 170 μ M and consisted of a variety of scaffolds (Figure 4). The calculated binding efficiency index (Abad-Zapatero and Metz, 2005) (Supplemental Information) indicates that these fragments are all very good or excellent starting points for hit elaboration projects.

As a second validation step, we carried out a more detailed kinetic analysis of the mode of action of the eight most potent fragments. Substrate-velocity experiments were performed in which either DsbA or UQ1 were titrated in the presence of saturating amounts of the other. The titrations were then repeated in the presence of increasing amounts of the inhibitory fragment (Figure 5; Supplemental Information). In this analysis, fragments 1–3 behaved similarly. This group is exemplified by fragment 2 where increasing concentrations result in moderate perturbation of the maximum enzymatic turn over rate (k_{cat}) and apparent affinity of DsbA but a dramatic reduction (>6-fold) in the apparent affinity of UQ1. These data suggest that fragments 1–3 compete for the same binding site as UQ1. On the other hand, addition of fragments 4–8 simultaneously decreased both the apparent affinity and the k_{cat} for UQ1 and DsbA as best exemplified by fragment 8 (Figure 5; Supplemental Information). These data suggest a mixed model of inhibition of DsbB by these fragments. We next sought biophysical confirmation of these two different modes of fragment interaction with DsbB.

Confirmation of Different Modes of Interaction with DsbB by NMR

Chemical shift perturbations of the protein NMR spectrum (typically 2D ^{15}N - 1H HSQC or ^{13}C - 1H HSQC) in the presence of compounds can both confirm binding to the target and localize the binding site on a protein when resonance assignments are available (Shuker et al., 1996). While the sequential assignment of wild-type DsbB is not available due to the poor quality of the NMR spectra, spectra of the DsbB[CSSC] double cysteine mutant are of high quality, resulting in a complete backbone resonance assignment for this form of the protein (Zhou et al., 2008). When purified from *E. coli*, DsbB[CSSC] contains the endogenous ubiquinone-8 (Bader et al., 1999), thus compounds specific for this site must compete with UQ8 for binding. We first titrated the synthetic quinone UQ1 into a sample of ^{15}N DsbB[CSSC]. Addition of UQ1 to ^{15}N DsbB[CSSC] resulted in numerous chemical shift perturbations but two in particular afford a detailed analysis of the binding and allow a reliable comparison with the fragments found in TINS screening. As shown in Figure 6, the side-chain indole of Trp135 (in the vicinity of the quinone binding site) (Supplemental Information) and the backbone amide of Arg109 (close to the DsbA binding site) respond very differently to addition of UQ1. Titration of UQ1 resulted in the simultaneous disappearance of the Trp135 ϵ -HN




peak from DsbB[CSSC] bound to endogenous quinone and the appearance of a new peak close by in the spectrum. Due to its proximity and the unique chemical shift of the Trp ϵ HN

suggesting that the fragments selected by TINS screening and biochemical assays on wild-type protein also bind the cysteine mutated form. The presence of chemical shift perturbations

proton, in combination with the high level of conservation of this residue, the new peak is likely from the Trp ϵ HN proton of the UQ1 bound DsbB[CSSC]. This pattern of peak changes is indicative of slow exchange on the NMR timescale (e.g., $k_{off} < 30$ Hz $\Delta\delta$ in Figure 6A). In contrast, the backbone amide of Arg109 is essentially unchanged by the addition of UQ1. Mapping the chemical shift perturbations induced by UQ1 onto the surface of DsbB confirms that UQ1 binds at the UQ8 site (Supplemental Information).

Addition of all eight fragments to 15 N-labeled DsbB[CSSC] resulted in detectable changes in chemical shifts,






Figure 6. NMR Analysis of Fragment Binding to DsbB

The eight most potent fragments were titrated into ^{15}N DsbB[CSSC]. Data for the synthetic quinone UQ1 (A), competitive fragment **2** (B), and the mixed model fragment **8** (C) are shown. For each of these three compounds, the structure of the compound is shown in the left column and the characteristic peak perturbations in the $^{[15}\text{N},^1\text{H}]$ HSQC spectrum (green 0 mM fragment, blue 5 mM fragment, and red 10 mM fragment) are shown in the middle (Tryptophan 135 side-chain indole) and right columns (Arginine 109 backbone amide). See also Figures S5 and S6.

both in solvent exposed loops and in portions of the protein buried within the micelle (data not shown) suggests that the fragments are specifically binding to the protein and not nonspecifically partitioning into the micelle. Fragment **2**, which competitively inhibited ubiquinone binding, induced chemical shift perturbations in a variety of amino acids, including W135 and R109. The pattern of chemical shift perturbations induced by fragment **2** closely resembles that induced by UQ1. First, titration of **2** into ^{15}N DsbB[CSSC] resulted in chemical shift changes in the W135 ϵ -HN peak that were similar to those induced by UQ1 (i.e., slow exchange). Moreover, the resonance frequency of the new peak tentatively assigned to the DsbB[CSSC]-**2** complex is similar to that of the DsbB[CSSC]-UQ1 complex. Similarly, R109HN, which is minimally affected by UQ1, undergoes

only minor chemical shift perturbations in the presence of **2**. Mapping the chemical shift perturbations induced by **2** onto the surface of DsbB confirms that binding is similar to UQ1 (Supplemental Information). While **1** and **3** induce chemical shift perturbations in the spectrum of DsbB[CSSC], the characteristic ones observed at R109 and W135 are not seen, so the grouping of these compounds with **2** as UQ8 competitors is tentative, relying only on the kinetic data.

In contrast, the chemical shift changes induced by fragments **4–8** differ in both the overall pattern and the details from fragment **2** and UQ1 (Figure 6C; Supplemental Information). Addition of **8**, for example, induced concentration dependent shifts in the Trp135 ϵ -HN resonance to an entirely different chemical shift than did fragment **2** or UQ1. This concentration dependent shift

is indicative of rapid exchange on the NMR timescale. There was no evidence for slow exchange for any of the fragments **4–8**, although **4** and **7** show signs of line broadening of the backbone resonance of Q33 that may indicate intermediate exchange (not shown). In contrast, the backbone amide of R109, which is only mildly perturbed by UQ1 or **2**, is very dramatically perturbed by the addition of fragment **8**. These data suggest that fragments **4–8**, which exhibit mixed mode DsbB inhibition, bind in either a different mode or different site to fragment **2** which is competitive with ubiquinone.

DISCUSSION

The use of Ro3-compliant, “drug fragments” as a starting point for drug discovery has delivered a number of innovative compounds against soluble targets which are currently in clinical trials (Hajduk and Greer, 2007). Membrane proteins have not made good targets for FBDD due to their challenging physicochemical properties. In particular, the difficulty of generating sufficient quantities of purified, functional protein and of detecting specific binding to the target, as opposed to nonspecific partitioning into hydrophobic phases, has limited the applicability of biophysical ligand screening approaches. Here, we have addressed these two issues by (a) immobilizing the target and reusing a single sample to screen an entire fragment collection and (b) using a reference sample to cancel out nonspecific interaction of the fragments with the hydrophobic phase. Using TINS we have screened a collection of nearly 1100 fragments with a single sample of less than 2 mg of protein and demonstrated that the protein was stable throughout the procedure. The stability of DsbB to repeated cycles of fragment application and washing depends on detergent micelles and the quinone cofactor. The detergent requirement could be overcome by including it in the buffer or using NDs to solubilize the protein. Endogenous UQ8 binds DsbB very tightly and is quite resistant to repeated detergent washing (Inaba et al., 2004).

Screening of the fragment library resulted in 93 ligands that were specific for DsbB. A number of observations suggest that most of these ligands are directly binding to DsbB and not indirectly via the micelle. First, the DsbB binding detected using TINS was relative to OmpA solubilized in identical conditions. Second, there is a range of potencies in the enzyme inhibition studies that includes a small number of noninhibitors and activators. Third, and perhaps more critically, inhibition is saturable and occurs over 2 log orders, strongly suggesting a stoichiometric interaction. Fourth, titration of eight different fragments into ¹⁵N-labeled DsbB resulted in chemical shift perturbations at well-defined sites in both solvent exposed and micelle buried portions of the protein. In particular, the similarity of the chemical shift perturbations induced by the synthetic quinone UQ1 and fragment **2** indicates the compounds are binding to the same or overlapping sites. An additional, likely important, factor contributing to the low false positive rate is that the fragments that make up the collection are highly soluble, with each having been tested at 500 μM in an aqueous buffer alone and in a mixture. Nonetheless, an appreciable fraction of these fragments exhibit sufficient nonspecific binding to the micelle that they were only poorly or even not detected in the NMR spectra. These data suggest that ligand screening in the presence of

micelle-solubilized membrane proteins may bias the chemical nature of the fragment library. The median cLogP for observable compounds in the presence of ND-solubilized proteins is slightly greater (0.9 versus 1.1) suggesting a reduced tendency of hydrophobic compounds to partition into the nanodisc.

The eight fragments with greatest potency in the single concentration enzyme inhibition assay were fully characterized for potency, mode of action, and binding site on DsbB. A simplistic analysis suggests that these fragments can be divided into two groups, one that competes only with quinone for DsbB binding and a second that perturbs the apparent affinity of DsbB for both quinone and DsbA. The different mode of action is best exhibited by the differing effect on the apparent K_m for UQ1 or DsbA for each. Addition of fragment **2** reduced K_m for UQ1 more than 8-fold, while it had only a marginal effect on the K_m for DsbA (only 5% greater than experimental error). In contrast, addition of **8** reduced K_m for UQ1 more than 4.4-fold and K_m for DsbA more than 2-fold.

The different behavior of the resonances of the backbone amide of R109 and the side-chain indole of W135 upon titration with the fragments provides further support for two modes of action. Titration of UQ1 DsbB[CSSC] results in slow exchange between the endogenous quinone bound form and a newly arising peak at a nearby position which we assign to the UQ1 complex. Similarly, addition of **2** resulted in slow exchange between the endogenous quinone bound form of W135ε NH and the appearance of a new peak with similar chemical shift as the UQ1 complex. An additional chemical shift perturbation indicating fast exchange with the endogenous complex was also observed. The fast exchange is likely due to competition between **2** and the quinone moiety of the bound UQ8, consistent with the competitive kinetics observed for this inhibitor. However, we have shown that the isoprenyl tail of UQ8 extends down the groove between TM1 and TM4, making extensive interactions with the protein (Zhou et al., 2008). Therefore, displacement of the isoprenyl moiety apparently occurs on a slower timescale. Addition of **8** to DsbB[CSSC] also causes chemical shift perturbation of the W135ε NH but these suggest rapid exchange between a typical 2-state equilibrium rather than the more complex effects seen with **2**. In addition, the bound state has a different resonance frequency than the bound state of UQ1 or **2**. Additional large downfield chemical shifts of the resonance of R109N, indicative of rapid exchange, are observed while UQ1 and **2** had no or only minor effects on this peak. From a drug discovery perspective, these data are exciting because it suggests, as with soluble enzymes, it is possible to find small molecule inhibitors with different modes of action and possibly nonoverlapping or even different binding sites on membrane proteins.

We note that the concentration of the fragments required to induce chemical shift perturbations in DsbB[CSSC] is significantly higher than the IC₅₀ values measured for the wild-type protein but the same as required for UQ1. A likely explanation is that the conformation of the mutant differs slightly from the wild-type protein, against which the fragments were selected. In addition, either the affinity for the quinone is higher for the DsbB[CSSC] mutant or, more likely, the quinone binding site may be partially occluded. This latter possibility is clearly consistent with the reduced dynamic behavior of DsbB[CSSC] with

respect to the wild-type protein, which results in the substantial improvement in the quality of the NMR spectra. This reduced dynamic behavior of the disulfide mutant may be responsible for the slow exchange kinetics observed for UQ1 and **2** if release of the UQ8 from this binding site can only occur from a sparsely populated conformation.

Functional solubilization of membrane proteins in detergent micelles is a challenging process that must be individually optimized for each protein. NDs offer the potential to enable a more generic approach to handling membrane proteins since they can be used to functionally solubilize a variety of membrane proteins and can obviate the requirement for an intermediate micelle-solubilized step (Katzen et al., 2008; Civjan et al., 2003). Furthermore, immobilization can be made generic for all MPs with minimal effect on functionality by appropriate engineering of the MSP portion of the ND. Use of NDs as a generic solubilization/immobilization system for ligand screening is further enabled by the stability of the empty ND and the fact that it represents a high-quality reference system to remove false positives. This conclusion is strongly supported by the observation that the eight DsbB/DPC-specific hits failed to inhibit DsbB/ND while seven of eight DsbB/ND hits also inhibited DsbB/DPC. Apparently, despite the reference sample, some compounds interact with DsbB in a micelle-specific manner. This problem would be largely eliminated by using NDs.

SIGNIFICANCE

Integral membrane proteins make up a significant portion of the human genome, carrying out numerous important normal as well as disease-related functions. More than 50% of drugs currently on the market target a membrane protein, demonstrating the utility of targeting this class of proteins. Approaches for the development of drugs targeting this class of proteins have focused principally on the use of high-throughput screening methods. Recently, fragment-based drug discovery (FBDD) has emerged as a powerful additional drug discovery approach. Because of the typically modest binding affinities of the small, functional group rich, i.e., high ligand efficiency, compounds utilized in FBDD, various biophysical techniques, including NMR, are typically used to detect binding. To date, several compounds developed using FBDD have advanced to clinical trials (Hajduk and Greer, 2007). However, thus far FBDD has been demonstrated only for soluble proteins, not membrane proteins.

Herein, we describe the first complete screen of a fragment collection against an integral membrane protein. The screen was performed using a detergent micelle-solubilized protein using a simple and rapid 1D NMR method we described previously (TINS). The 93 hits were subsequently validated in an enzyme inhibition study. The use of a reference sample in the TINS experiment eliminated the well-documented problem of nonspecific binding of compounds to the detergent. As membrane protein activity is enhanced in more bilayer-like environments, we have also solubilized the protein in NDs and shown that the screening approach is effective with this preparation as well. The use of NDs further ameliorates issues with nonspecific binding and

should also extend the method to proteins which typically do not behave well in detergents such as GPCRs.

Our results clearly establish the feasibility of using a fragment-based approach for finding starting matter for subsequent development of compounds targeting membrane proteins, including the all-important GPCR class of proteins. In addition, increasing success in the preparation of membrane proteins in reasonable quantities should make many such proteins amenable to the use of TINS for fragment screening, thereby increasing its general utility.

EXPERIMENTAL PROCEDURES

Protein Purification

DsbA, DsbB, and OmpA were expressed and purified as previously reported (Bader et al., 1999, 2000; Arora et al., 2000). All proteins have a 6x-His tag at the N terminus or C terminus for affinity purification. Successful refolding of OmpA from inclusion bodies was monitored by SDS-PAGE analysis (Arora et al., 2000).

ND Self-Assembly

The ND self assembly procedure was repeated the same way for both OmpA and DsbB with slight adaptations from the previously reported procedures (Civjan et al., 2003). The reconstitution mixture contained Membrane Scaffold Protein MSP1D1(-) which lacked the His tag, with mixed micelles of POPC and cholate at a ratio of 1:65:130. This reconstitution mixture was added to the OmpA or DsbB in detergent micelles (each with 10x the detergent CMC) in a volumetric ratio of 1:1 and incubated on ice for 4 hr. We always ensured a stoichiometry of MSP1D1(-) to OmpA or DsbB of 2:1. Upon addition of 0.7 g/ml of the hydrophobic adsorbent Bio-Beads SM-2 (Biorad, Hercules, CA) and gently mixing for 4 hr at 4°C, the NDs underwent self-assembly, incorporating DsbB or OmpA in the lipid bilayer. This step was limiting, whereby detergent removal before 4 hr resulted in incomplete ND formation, but caused ND complex malformation if carried out for longer (i.e., 16 hr, data not shown). The His tag of the embedded OmpA and DsbB was used to separate the empty nontagged MSP1D1(-) complexes from the mixture by IMAC chromatography using Ni-NTA resin in a buffer containing 100 mM Tris-HCl (pH 7.5), 300 mM NaCl, and imidazole at 0, 10, and 100 mM for loading, washing, and elution, respectively. The eluted fractions were applied to a gel filtration column (Superdex 200 10/300 from GE Healthcare) in order to remove the remaining aggregated, nonembedded OmpA and DsbB, and to exchange the ND-embedded proteins into phosphate buffered saline (PBS, pH 7.4) for compatibility with the immobilization step required for TINS. A set of standard proteins was used to calibrate the Stokes' diameter versus the retention time of the column.

Protein Immobilization

Actigel ALD resin (Sterogene, Carlsbad, CA) was used as a 50% slurry and all experiments were carried out at 4°C when possible. The resin was washed with cold phosphate buffer (50 mM Na₂HPO₄, 50 mM KH₂HPO₄, 100 mM NaCl [pH 7.5]). Two hundred nanomoles of DPC-solubilized DsbB was added to 1 ml bed volume of resin. The reductant sodium cyanoborohydride (NaCNBH₃) was added to a final concentration of 0.1 M. After an overnight incubation at 4°C, residual unreacted aldehydes were blocked by addition of 50 mM D₁₁-Tris and fresh NaCNBH₃ in the same buffer for another 2 hr. The same procedure was repeated for DPC-solubilized OmpA. Quantification of immobilized protein was monitored by absorption of the supernatant at 280 nm before and after immobilization, and by SDS-page gel with a known standard curve and band volume analysis. These data indicated that a final concentration of 100 μM of both immobilized DsbB and OmpA was achieved, equating to a 50% yield. The procedure was repeated identically to immobilize DsbB and OmpA solubilized in ND (after pooling fractions containing particles ranging between 9.2 and 9.7 nm) and empty ND at a similar final concentration as the micelle-solubilized protein. ND preparations could not be quantified by UV absorption; therefore, they were loaded on SDS-page gels with a BSA standard curve for band volume quantification by Quantity One (Biorad),

providing information on the concentration and ratio of ND molecules and incorporated proteins. The yield of immobilized, ND-solubilized protein was 75%.

DsbB Activity Assays

DsbB activity was quantified by measuring the capacity of the enzyme to reoxidize the protein DsbA or reduce its cofactor ubiquinone-5, also called coenzyme Q1 (UQ1) (pH 6.2). DsbA was reduced with 10 mM DTT for 10 min on ice. DTT was subsequently removed by gel filtration on a PD-10 column pre-equilibrated with degassed, distilled water containing 0.1 mM EDTA. DsbA fluorescence (excitation at 295 nm and emission at 330 nm) was measured in the presence of DsbB and UQ1 in 50 mM sodium phosphate, 100 mM NaCl, 0.1% detergent [DPC or DDM depending on which was used to solubilize DsbB], and 0.1 mM EDTA at 30°C. Both UQ1 and DsbA were added at final concentrations of 30 μ M. DsbB was added at a final concentration of 20 nM. The activity of DsbB in terms of moles ubiquinone reduced/moles DsbB min^{-1} could be calculated by using the initial slope of the fluorescence decrease upon DsbA oxidation, or by using the slope of absorption decrease at 275 nm upon reduction of UQ1 (Bader et al., 1999).

To measure activity of immobilized DPC- or ND-solubilized DsbB, resin was aliquoted and diluted with degassed activity assay buffer to a final protein concentration of approximately 20 nM. For an appropriate baseline, an equivalent amount of resin without protein (blank resin) was prepared in the same manner. Quinone reduction was monitored in DPC samples after addition of 20 μ M coenzyme Q1 and 20 μ M DsbA and DsbA oxidation was measured for ND-solubilized DsbB.

Target Immobilized NMR Screening

Immobilized, DPC-solubilized DsbB and OmpA were each packed into a separate cell of a dual-cell sample holder (Marquardsen et al., 2006). Mixes of the 1071 fragments were made by 200-fold dilution of a 100 mM stock of each compound in d_6 -DMSO such that the final DMSO concentration was never greater than 5%. Upon injection of each mix into the dual-cell sample holder, flow was stopped and spatially selective Hadamard spectroscopy (Murali et al., 2006) was used to acquire a 1D ^1H spectrum of each sample separately. A CPMG T2 filter of 80 ms was used to remove residual broad resonances from the Sepharose resin. The cycle time was about 35 min, with 30 min required for the NMR experiment and 5 min for sample handling, resulting in a total time of about 5.5 days to complete the screen. To maintain the proper fold of each protein, 5 mM deuterated DPC was included in the buffer (20 mM phosphate buffer in D_2O , 100 mM NaCl [pH 7.6]) used to wash the fragment mixes from the sample holder.

Biochemical Hit Validation

All fragments from the screen that were designated as positive for binding were assayed for DsbB inhibition at 250 μ M. The amount of DMSO in all biochemical assay controls was adjusted to match the amount present when fragments were tested. Those compounds that showed more than 70% inhibition at 250 μ M were further characterized by titration from 0.0001 to 10 mM to generate IC_{50} curves. The mode of action for the eight most potent fragments was determined from competition enzyme assays. For this analysis either DsbA or UQ1 was titrated in from 0.2 to 40 μ M, while the other was kept constant at 40 μ M. For each titration point, slopes were measured in the presence of 5, 10, and 75 μ M of the fragment. DsbB activity data were analyzed using the nonlinear regression curve fitting routines in Graph Pad Prism v. 5.01 (Graph Pad, San Diego, CA). Statistical significance was evaluated with the Student's *t* test. Depending on the light absorbing properties of the fragments, they were used in either the fluorescence or UV-absorbance assay. Compounds which were not compatible with the assays due to high intrinsic fluorescence, high UV absorbance, or irregular baselines were not included in the analysis.

Biophysical Hit Validation

Due to the poor quality of the NMR spectra of the wild-type DsbB, it was necessary to use a mutant that represents an intermediate in the disulfide oxidation pathway (Zhou et al., 2008). Validated hits from the screen were titrated at 1, 5, and 10 mM into ^{15}N -labeled DsbB[CS5C] mutant (C44S, C104S). [^{15}N , ^1H] HSQC experiments were acquired at 40°C in a Bruker DRX 600 MHz spectrometer equipped with a cryoprobe. A reference titration of

DMSO and a nonbinding fragment from the screen were used to subtract chemical shift perturbations not related to fragment binding.

SUPPLEMENTAL INFORMATION

Supplemental Information includes six figures and three tables and can be found with this article online at doi:10.1016/j.chembiol.2010.06.011.

ACKNOWLEDGMENTS

G.S. acknowledges greater than 5% ownership in a company, ZoBio BV, whose goal is to commercialize TINS-based drug discovery. This research was supported in part by the Dutch Technology Foundation STW, applied science division of NWO and the Technology Program of the Ministry of Economic Affairs. This work was also supported by the US National Institutes of Health (R01 GM078296).

Received: February 17, 2010

Revised: May 29, 2010

Accepted: June 2, 2010

Published: August 26, 2010

REFERENCES

- Abad-Zapatero, C., and Metz, J.T. (2005). Ligand efficiency indices as guideposts for drug discovery. *Drug Discov. Today* 10, 464–469.
- Arora, A., Abildgaard, F., Bushweller, J.H., and Tamm, L.K. (2001). Structure of outer membrane protein A transmembrane domain by NMR spectroscopy. *Nat. Struct. Biol.* 8, 334–338.
- Arora, A., Abildgaard, F., Bushweller, J.H., and Tamm, L.K. (2002). NMR solution structure and dynamics of the outer membrane protein A transmembrane domain in dodecylphosphocholine micelles. *Biophys. J.* 82, 2512.
- Arora, A., Rinehart, D., Szabo, G., and Tamm, L.K. (2000). Refolded outer membrane protein A of *Escherichia coli* forms ion channels with two conductance states in planar lipid bilayers. *J. Biol. Chem.* 275, 1594–1600.
- Bader, M., Muse, W., Ballou, D.P., Gassner, C., and Bardwell, J.C.A. (1999). Oxidative protein folding is driven by the electron transport system. *Cell* 98, 217–227.
- Bader, M.W., Xie, T., Yu, C.A., and Bardwell, J.C.A. (2000). Disulfide bonds are generated by quinone reduction. *J. Biol. Chem.* 275, 26082–26088.
- Bardwell, J.C.A., Lee, J.O., Jander, G., Martin, N., Belin, D., and Beckwith, J. (1993). A pathway for disulfide bond formation in vivo. *Proc. Natl. Acad. Sci. USA* 90, 1038–1042.
- Carr, R.A.E., Congreve, M., Murray, C.W., and Rees, D.C. (2005). Fragment-based lead discovery: leads by design. *Drug Discov. Today* 10, 987–992.
- Civjan, N.R., Bayburt, T.H., Schuler, M.A., and Sligar, S.G. (2003). Direct solubilization of heterologously expressed membrane proteins by incorporation into nanoscale lipid bilayers. *Biotechniques* 35, 556.
- Congreve, M., Carr, R., Murray, C., and Jhoti, H. (2003). A rule of three for fragment-based lead discovery? *Drug Discov. Today* 8, 876–877.
- Dahmane, T., Damian, M., Mary, S., Popot, J.L., and Baneres, J.L. (2009). Amphipol-Assisted in Vitro Folding of G Protein-Coupled Receptors. *Biochemistry* 48, 6516–6521.
- Früh, V., Heetebrij, R.J., and Siegal, G. (2008). Target immobilized NMR screening: Validation and extension to membrane proteins. In *Fragment-Based Drug Discovery, A Practical Approach*, E.R. Zartler and M. Shapiro, eds. (Chichester, UK: Wiley), pp. 135–158.
- Hajduk, P.J., and Greer, J. (2007). A decade of fragment-based drug design: strategic advances and lessons learned. *Nat. Rev. Drug Discov.* 6, 211–219.
- Hajduk, P.J., Meadows, R.P., and Fesik, S.W. (1997). Drug design—discovering high-affinity ligands for proteins. *Science* 278, 497–499.
- Inaba, K., and Ito, K. (2002). Paradoxical redox properties of DsbB and DsbA in the protein disulfide-introducing reaction cascade. *EMBO J.* 21, 2646–2654.

- Inaba, K., Murakami, S., Suzuki, M., Nakagawa, A., Yamashita, E., Okada, K., and Ito, K. (2006). Crystal structure of the DsbB-DsbA complex reveals a mechanism of disulfide bond generation. *Cell* 127, 789–801.
- Inaba, K., Takahashi, Y.H., and Ito, K. (2004). DsbB elicits a red-shift of bound ubiquinone during the catalysis of DsbA oxidation. *J. Biol. Chem.* 279, 6761–6768.
- Jagusztyn-Krynicka, E.K., Rybacki, J., and Lasica, A.M. (2009). Novel strategies for antibacterial drug discovery—antitoxin drugs. *Postepy Mikrobiologii* 48, 93–104.
- Jander, G., Martin, N.L., and Beckwith, J. (1994). Two cysteines in each periplasmic domain of the membrane-protein DsbB are required for its function in protein disulfide bond formation. *EMBO J.* 13, 5121–5127.
- Kadokura, H., Bader, M., Tian, H.P., Bardwell, J.C.A., and Beckwith, J. (2000). Roles of a conserved arginine residue of DsbB in linking protein disulfide-bond-formation pathway to the respiratory chain of *Escherichia coli*. *Proc. Natl. Acad. Sci. USA* 97, 10884–10889.
- Katzen, F., Fletcher, J.E., Yang, J.P., Kang, D., Peterson, T.C., Cappuccio, J.A., Blanchette, C.D., Sulchek, T., Chromy, B.A., Hoepflich, P.D., et al. (2008). Insertion of membrane proteins into discoidal membranes using a cell-free protein expression approach. *J. Proteome Res.* 7, 3535–3542.
- Leitz, A.J., Bayburt, T.H., Barnakov, A.N., Springer, B.A., and Sligar, S.G. (2006). Functional reconstitution of beta(2)-adrenergic receptors utilizing self-assembling Nanodisc technology. *Biotechniques* 40, 601.
- Marquardsen, T., Hofmann, M., Hollander, J.G., Loch, C.M.P., Kihne, S.R., Engelke, F., and Siegal, G. (2006). Development of a dual cell, flow-injection sample holder, and NMR probe for comparative ligand-binding studies. *J. Magn. Reson.* 182, 55–65.
- Murali, N., Miller, W.M., John, B.K., Avizonis, D.A., and Smallcombe, S.H. (2006). Spectral unraveling by space-selective Hadamard spectroscopy. *J. Magn. Reson.* 179, 182–189.
- Nath, A., Atkins, W.M., and Sligar, S.G. (2007). Applications of phospholipid bilayer nanodiscs in the study of membranes and membrane proteins. *Biochemistry* 46, 2059–2069.
- Rasmussen, S.G.F., Choi, H.K., Rosenbaum, D.M., Kobilka, T.S., Thian, F.S., Edwards, P.C., Burghammer, M., Ratnala, V.R.P., Sanishvili, R., Fischetti, R.F., et al. (2007). Crystal structure of the human beta 2 adrenergic G-protein-coupled receptor. *Nature* 450, 383–387.
- Regeimbal, J., and Bardwell, J.C.A. (2002). DsbB catalyzes disulfide bond formation de novo. *J. Biol. Chem.* 277, 32706–32713.
- Serrano-Vega, M.J., Magnani, F., Shibata, Y., and Tate, C.G. (2008). Conformational thermostabilization of the beta 1-adrenergic receptor in a detergent-resistant form. *Proc. Natl. Acad. Sci. USA* 105, 877–882.
- Shuker, S.B., Hajduk, P.J., Meadows, R.P., and Fesik, S.W. (1996). Discovering high-affinity ligands for proteins: SAR by NMR. *Science* 274, 1531–1534.
- Siegal, G., AB, E., and Schultz, J. (2007). Integration of fragment screening and library design. *Drug Discov. Today* 12, 1032–1039.
- Stenson, T.H., and Weiss, A.A. (2002). DsbA and DsbC are required for secretion of pertussis toxin by *Bordetella pertussis*. *Infect. Immun.* 70, 2297–2303.
- Vanwetswinkel, S., Heetebrij, R.J., van Duynhoven, J., Hollander, J.G., Filippov, D.V., Hajduk, P.J., and Siegal, G. (2005). TINS, target immobilized NMR screening: an efficient and sensitive method for ligand discovery. *Chem. Biol.* 12, 207–216.
- Zheng, C.J., Han, L., Yap, C.W., Xie, B., and Chen, Y.Z. (2006). Progress and problems in the exploration of therapeutic targets. *Drug Discov. Today* 11, 412–420.
- Zhou, Y., Cierpicki, T., Jimenez, R.H., Lukasik, S.M., Ellena, J.F., Cafiso, D.S., Kadokura, H., Beckwith, J., and Bushweller, J.H. (2008). NMR solution structure of the integral membrane enzyme DsbB: Functional insights into DsbB-catalyzed disulfide bond formation. *Mol. Cell* 31, 896–908.